NYSE$INSP
Inspire Medical Systems Inc. · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Inspire Medical Systems reported strong Q4 2024 results, achieving $239.7 million in revenue, a 25% year-over-year increase. Net income rose significantly to $35.2 million, with a diluted EPS of $1.15. Operating income surged to $31.9 million, supported by an 85.0% gross margin. The company activated 72 new U.S. centers and added 12 new sales territories, contributing to growth momentum.
Headline financials
Revenue & EPS history
Inspire · Revenue · Quarterly
$240M
Forward guidance
Inspire expects continued growth in 2025, projecting revenue between $940 million and $955 million, reflecting 17-19% year-over-year growth. Diluted EPS is forecasted between $2.10 and $2.20, with gross margins anticipated in the 84-86% range.
Tailwinds
- Revenue guidance increased to $940M-$955M for FY 2025.
- Expected EPS growth to $2.10-$2.20.
- Continued expansion with new sales territories and centers.
- Strong demand for Inspire V therapy driving adoption.
- Stable gross margin projection between 84-86%.
Headwinds
- Increased operating expenses due to expansion efforts.
- Potential headwinds from regulatory changes.
- Macroeconomic uncertainty may impact demand.
- Stock repurchase program could impact liquidity.
- Competitive pressures in the sleep apnea market.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+2.4%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+3.3%
Avg return
30 days after
69%
22 / 32 earnings
Positive
+34.4%
Q3 2020
Best reaction
-34.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.2% | -19.2% | -23.1% | |
| Q4 2025 | -12.5% | -11.5% | -14.1% | |
| Q3 2025 | +15.6% | +11.0% | +90.0% | |
| Q1 2025 | +1.6% | -4.7% | -14.4% | |
| Q4 2024 | +1.7% | +2.6% | -12.2% | |
| Q3 2024 | +4.3% | +3.1% | +3.3% | |
| Q2 2024 | +29.5% | +32.8% | +35.6% | |
| Q1 2024 | -34.9% | -33.1% | -37.7% | |
| Q4 2023 | -6.5% | -9.8% | -4.8% | |
| Q3 2023 | -20.9% | -23.5% | -2.1% | |
| Q2 2023 | -3.5% | -3.7% | -21.2% | |
| Q1 2023 | +5.0% | +5.8% | +15.3% | |
| Q4 2022 | +9.7% | +7.9% | -0.4% | |
| Q3 2022 | +6.0% | +6.4% | +22.9% | |
| Q2 2022 | +4.4% | +4.0% | -11.0% | |
| Q1 2022 | -4.5% | -19.8% | -14.4% | |
| Q4 2021 | +5.4% | +0.6% | -1.4% | |
| Q3 2021 | +1.3% | +4.1% | -16.0% | |
| Q2 2021 | +12.9% | +14.4% | +26.1% | |
| Q1 2021 | -16.0% | -17.4% | -29.6% | |
| Q4 2020 | +3.4% | +4.1% | -11.4% | |
| Q3 2020 | +34.4% | +40.7% | +60.3% | |
| Q2 2020 | +7.4% | +3.5% | +17.9% | |
| Q1 2020 | +3.7% | +6.2% | +26.1% | |
| Q4 2019 | +6.4% | +7.7% | -27.2% | |
| Q3 2019 | +4.3% | +4.8% | +21.7% | |
| Q2 2019 | +4.5% | +1.9% | +7.3% | |
| Q1 2019 | -2.5% | -5.7% | -0.6% | |
| Q4 2018 | +5.4% | +5.0% | -4.5% | |
| Q3 2018 | +15.4% | +1.8% | -9.9% | |
| Q2 2018 | -1.8% | -0.1% | +15.6% | |
| Q1 2018 | +10.0% | +6.4% | +20.5% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro